JP2003504303A - 器質性障害から派生する障害の治療 - Google Patents

器質性障害から派生する障害の治療

Info

Publication number
JP2003504303A
JP2003504303A JP2000584874A JP2000584874A JP2003504303A JP 2003504303 A JP2003504303 A JP 2003504303A JP 2000584874 A JP2000584874 A JP 2000584874A JP 2000584874 A JP2000584874 A JP 2000584874A JP 2003504303 A JP2003504303 A JP 2003504303A
Authority
JP
Japan
Prior art keywords
disorder
disorders
sibutramine
symptoms
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000584874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003504303A5 (https=
Inventor
ピーター・スターリング・ミュラー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2003504303A publication Critical patent/JP2003504303A/ja
Publication of JP2003504303A5 publication Critical patent/JP2003504303A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000584874A 1998-12-02 1999-12-01 器質性障害から派生する障害の治療 Pending JP2003504303A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/204,124 1998-12-02
US09/204,124 US6323242B1 (en) 1998-12-02 1998-12-02 Treatment of disorders secondary to organic impairments
PCT/US1999/028362 WO2000032178A2 (en) 1998-12-02 1999-12-01 Use of siburamine for the treatment of disorders of the central nervous system secondary to organic impairments

Publications (2)

Publication Number Publication Date
JP2003504303A true JP2003504303A (ja) 2003-02-04
JP2003504303A5 JP2003504303A5 (https=) 2007-02-01

Family

ID=22756736

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000584874A Pending JP2003504303A (ja) 1998-12-02 1999-12-01 器質性障害から派生する障害の治療

Country Status (8)

Country Link
US (2) US6323242B1 (https=)
EP (1) EP1135115B1 (https=)
JP (1) JP2003504303A (https=)
AT (1) ATE329588T1 (https=)
AU (1) AU764049B2 (https=)
CA (1) CA2353133C (https=)
DE (1) DE69931957T2 (https=)
WO (1) WO2000032178A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007034910A1 (ja) * 2005-09-22 2007-03-29 Eisai R & D Management Co., Ltd. 過食症及び過食症に伴ううつ病の治療用医薬組成物
JP2020533295A (ja) * 2017-09-07 2020-11-19 エヌエルエス−１ ファルマ アーゲー ヘロイン依存症及び物質使用障害のためのマジンドール治療

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339106B1 (en) * 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6803387B1 (en) * 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
WO2002069254A2 (en) 2001-02-22 2002-09-06 Classen Immunotherapies, Inc. Improved algorithms and methods for products safety
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
DE60220825T2 (de) * 2001-11-30 2008-03-06 Eli Lilly And Co., Indianapolis Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
US20030195186A1 (en) * 2002-04-10 2003-10-16 University Of Florida Methods of treating medication-, substance-, disease-, and other medical condition-related sexual dysfunction
US20030232805A1 (en) * 2002-04-24 2003-12-18 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
EP1513529B1 (en) 2002-05-30 2011-12-14 NeuroSearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
US20070032554A1 (en) * 2003-08-27 2007-02-08 Elililly And Company A Corporation Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
EP1830844A1 (en) * 2004-12-27 2007-09-12 Alpha 2 Pharmaceutical AB Antidepressant medicament comprising idazoxan and a selective serotonin reuptake inhibitor
ES3012497T3 (en) 2005-10-12 2025-04-09 Besins Healthcare Lu Sarl Improved testosterone gel and method of use
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
WO2008034142A2 (en) 2006-09-15 2008-03-20 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
WO2008042773A2 (en) * 2006-09-29 2008-04-10 Pdxrx, Inc. Unitary pharmaceutical composition, method, and kit for the treatment or prevention of metabolic or endocrine disorders
WO2008051610A2 (en) * 2006-10-26 2008-05-02 Mclean Hospital Corporation, The Treatment of impulse control disorders
RU2642074C2 (ru) 2011-12-30 2018-01-24 Ревива Фармасьютикалс, Инк. Композиции, синтез и способы применения производных фенилциклоалкилметиламина
US11033554B2 (en) 2015-07-24 2021-06-15 United States Government As Represented By The Department Of Veterans Affairs Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01250315A (ja) * 1988-03-31 1989-10-05 Kaken Pharmaceut Co Ltd 脳機能改善剤
JPH07508281A (ja) * 1992-06-23 1995-09-14 セプラコア　インコーポレーテッド 光学的に純粋な（＋）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物
JPH08500093A (ja) * 1992-06-23 1996-01-09 セプラコア インコーポレーテッド 光学的に純粋な（−）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物
JP2002523366A (ja) * 1998-08-24 2002-07-30 セプラコア インコーポレーテッド ドーパミン再取込みインヒビターを含有する組成物及びその使用方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443449A (en) 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
GB8531071D0 (en) 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5780051A (en) 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
US5459164A (en) 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9402641D0 (en) 1994-02-11 1994-04-06 Boots Co Plc Therapeutic agents
US5663178A (en) 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
GB9406857D0 (en) 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
US5795880A (en) 1996-12-30 1998-08-18 Louisiana State University Medical Center Foundation Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US5804596A (en) 1997-02-27 1998-09-08 Sabinsa Corporation Method of preparing a forskohlin composition from forskohlin extract and use of forskohlin for promoting lean body mass and treating mood disorders
US5922341A (en) 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
US6075028A (en) 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01250315A (ja) * 1988-03-31 1989-10-05 Kaken Pharmaceut Co Ltd 脳機能改善剤
JPH07508281A (ja) * 1992-06-23 1995-09-14 セプラコア　インコーポレーテッド 光学的に純粋な（＋）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物
JPH08500093A (ja) * 1992-06-23 1996-01-09 セプラコア インコーポレーテッド 光学的に純粋な（−）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物
JP2002523366A (ja) * 1998-08-24 2002-07-30 セプラコア インコーポレーテッド ドーパミン再取込みインヒビターを含有する組成物及びその使用方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007034910A1 (ja) * 2005-09-22 2007-03-29 Eisai R & D Management Co., Ltd. 過食症及び過食症に伴ううつ病の治療用医薬組成物
JP2020533295A (ja) * 2017-09-07 2020-11-19 エヌエルエス−１ ファルマ アーゲー ヘロイン依存症及び物質使用障害のためのマジンドール治療
US11596622B2 (en) 2017-09-07 2023-03-07 Nls Pharmaceutics Ag Mazindol treatment for heroin dependence and substance use disorder
JP7593619B2 (ja) 2017-09-07 2024-12-03 エヌエルエス－１ ファルマ アーゲー ヘロイン依存症及び物質使用障害のためのマジンドール治療

Also Published As

Publication number Publication date
AU764049B2 (en) 2003-08-07
DE69931957T2 (de) 2007-01-25
AU1748800A (en) 2000-06-19
DE69931957D1 (de) 2006-07-27
CA2353133A1 (en) 2000-06-08
US6323242B1 (en) 2001-11-27
US20030207943A1 (en) 2003-11-06
WO2000032178A3 (en) 2000-10-05
EP1135115B1 (en) 2006-06-14
EP1135115A2 (en) 2001-09-26
WO2000032178A2 (en) 2000-06-08
ATE329588T1 (de) 2006-07-15
CA2353133C (en) 2009-11-03

Similar Documents

Publication Publication Date Title
JP2003504303A (ja) 器質性障害から派生する障害の治療
Billiard et al. EFNS guidelines on management of narcolepsy
US20060252761A1 (en) Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
CN1413111A (zh) 右美沙芬和氧化酶抑制剂使患者摆脱麻醉药和抗抑郁药的用途
UA75580C2 (uk) Застосування дапоксетину або його фармацевтично прийнятної солі в лікарському засобі для лікування розладу статевої функції та промисловий виріб для його застосування
Goadsby Migraine and other primary headache disorders
US6696495B2 (en) Treatment of disorders secondary to organic impairments
AU2002258820A1 (en) Treatment of disorders secondary to organic impairments
Polatin et al. Integration of pharmacotherapy with psychological treatment of chronic pain
Billiard et al. Narcolepsy
US6132754A (en) Method for helping a patient eliminate tobacco dependency
Sadek Clinician's guide to psychopharmacology
Csiernik The essential guide to psychoactive drugs in Canada: a resource for counselling professionals
Dose Recognition and management of acute neuroleptic-induced extrapyramidal motor and mental syndromes
US8841300B2 (en) Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
Sinclair et al. Drugs to Treat Substance Use Disorders
Labus Clinical pharmacology made incredibly easy!
Linden Postmarketing surveillance of psychotherapeutic medications. A challenge for the 1990s
MALETTA Use of Antipsychotic Medication in the
Fymat Tourette's syndrome: III. Treatment Portfolio and Prognosis
Bentvelzen Addiction treatment for the fight against Anorexia Nervosa
Harris et al. Pharmacological Interventions
Gautam et al. Clinical practice guidelines for manage‐ment of opioid dependence
Chung Neurobiological Bases
Seidman et al. Biological and clinical perspectives on nicotine addiction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100608